Enamine Ltd has announced that it has signed a collaboration agreement with the Medical Research Council Laboratory of Molecular Biology (MRC LMB), Cambridge, UK, and the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic (IOCB), Prague, Czech Republic.
The new alliance is aimed at discovering novel Rhomboid Protease inhibitors as potential drugs to treat infectious, parasitic, oncological, immune and cardiovascular diseases.
Under the terms of the agreement, Enamine will provide the MRC LMB and IOCB with access to its integrated drug discovery capabilities, including Molecular Modeling, Compound Library, Screening Assays, Hit Finding and Characterization, Hit to Lead Chemistry and ADMET.
The three parties will jointly own the Intellectual Property resulting from this programme and will seek to partner the small molecule inhibitors generated with pharmaceutical companies for onward clinical development.
The collaboration agreement was negotiated by MRC Technology on behalf of MRC LMB.
Dr. Sergey Zozulya, Vice President, Biology at Enamine, said: "We are delighted to launch this collaboration with high calibre partners, demonstrating the interest of prominent academics in realizing the translational potential of their scientific discoveries through an alliance with Enamine. This alliance reflects our strategy to apply our integrated discovery platform, cost effective solutions and state-of-the-art technologies to create valuable IP for our partners and clients. With our recently introduced High Throughput Screening and bioanalytical service components, we have added capability to boost productivity."
Dr. Matthew Freeman, Head of Cell Biology Division at MRC LMB, commented: "We anticipate a very successful relationship with Enamine. This project provides evidence of the ability of our respective research centers to recognize valuable drug discovery models.”
Dr. Kvido Strisovsky, Group Leader at IOCB, said: "We are delighted to be part of this collaboration and we hope that the project will realize its full potential for the benefit of patients.”